Neumora Therapeutics has raised $112m in a Series B financing round to advance its new precision medicine candidates pipeline for neuropsychiatric disorders and neurodegenerative diseases.

New and existing investors including F-Prime Capital, Altitude Life Science Ventures , Mubadala Capital , Amgen , Exor Ventures, ARCH Venture Partners , Invus, Abu Dhabi Growth Fund (ADG), Newpath Partners, Polaris Partners , as well as other undisclosed investors have participated in the financing round.

Neumora has raised nearly $650m in capital to date.

The company also intends to use the funding to develop its precision neuroscience platform.

Recently, it completed subject enrolment in a Phase IIa clinical trial of NMRA-140, which is a kappa opioid receptor antagonist in development to treat the major depressive disorder.

Next year, Neumora plans to advance the clinical-stage vasopressin 1a receptor antagonist, NMRA-511, and an M4 muscarinic receptor-positive allosteric modulator, NMRA-266, into Phase I development for schizophrenia.

Neumora co-founder, chairman and CEO Paul Berns said: “This Series B financing reflects Neumora’s continued progress in building a best-in-class neuroscience company, including assembling a world-class team, scaling up an industry-leading data science and translational neuroscience platform, and advancing a broad and growing pipeline of seven development programs, including our internal discovery efforts and business development activities.

“This considerable amount of progress in such a short period of time reflects our urgency to address the relative lack of progress and innovation in neuroscience with our data-driven, precision medicine approach.”

The company’s earlier-stage pipeline includes several preclinical candidates’ development, including neurodegeneration programmes which are focused on Parkinson’s disease and amyotrophic lateral sclerosis (ALS).